Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, randomized, placebo-controlled crossover study to assess the efficacy of AST-120 in patients with gastroesophageal reflux disease (GERD) who continue to be symptomatic on a standard dose of proton pump inhibitor (PPI).

Trial Profile

A double-blind, randomized, placebo-controlled crossover study to assess the efficacy of AST-120 in patients with gastroesophageal reflux disease (GERD) who continue to be symptomatic on a standard dose of proton pump inhibitor (PPI).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2011

At a glance

  • Drugs Charcoal (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ocera Therapeutics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 24 Jun 2008 Actual patient number (4) added as reported by ClinicalTrials.gov.
    • 24 Jun 2008 The expected completion date for this trial has been changed from July 2008 to June 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top